Baseline Tumor Size as a Predictive and Prognostic Factor of Immune Checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer-Reference-Cited by-同舟云学术

Baseline Tumor Size as a Predictive and Prognostic Factor of Immune Checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer

Published:2019-02 Issue:2 Volume:39 Page:815-825
ISSN:0250-7005
Container-title:Anticancer Research
language:en
Short-container-title:Anticancer Res

Author:

KATSURADA MASAHIRO,NAGANO TATSUYA,TACHIHARA MOTOKO,KIRIU TATSUNORI,FURUKAWA KOICHI,KOYAMA KIYOKO,OTOSHI TAKEHIRO,SEKIYA REINA,HAZAMA DAISUKE,TAMURA DAISUKE,NAKATA KYOSUKE,KATSURADA NAOKO,YAMAMOTO MASATSUGU,KOBAYASHI KAZUYUKI,NISHIMURA YOSHIHIRO

Publisher

Anticancer Research USA Inc.

Subject

Cancer Research,Oncology,General Medicine

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Two nomograms constructed for predicting the efficacy and prognosis of advanced non‑small cell lung cancer patients treated with anti‑PD‑1 inhibitors based on the absolute counts of lymphocyte subsets;Cancer Immunology, Immunotherapy;2024-06-04

2. Organ‐specific responses to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma: A multicentre, retrospective study;Liver International;2024-04-15

3. Prognostic significance of initial tumor shrinkage in patients with stage III non-small cell lung cancer treated with durvalumab following chemoradiotherapy;International Journal of Clinical Oncology;2023-11-30

4. C-Reactive Protein as an Early Predictor of Efficacy in Advanced Non-Small-Cell Lung Cancer Patients: A Tumor Dynamics-Biomarker Modeling Framework;Cancers;2023-11-15

5. Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non–Small Cell Lung Cancer;JAMA Oncology;2023-11-01